Maria Angeles V. S.
- Country
- Spain
- Department
- Oncology
Research Overview
- Safety and Preliminary Efficacy of Azeliragon with Radiation and Temozolomide in Newly Diagnosed Glioblastoma Patients
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Vorasidenib in Residual or Recurrent Grade 2 Glioma with IDH1/IDH2 Mutation
- Evaluation of Berubicin Hydrochloride Versus Lomustine in Adult Patients with Recurrent Glioblastoma Multiforme Post-Standard Therapy Failure
Data & Insights
Has run more than one trial at 26 of 78 partner sites.
Specializations
Breast Cancer Therapeutics
Focus on advanced and early‑stage breast cancer subtypes, integrating endocrine, targeted and immunologic strategies.
- Hormone receptor‑positive, HER2‑negative disease
- HER2‑positive and HER2‑low tumors
- Triple‑negative breast cancer
- Neoadjuvant CDK4/6 inhibition
Trials address disease progression after prior chemotherapy and resistance mechanisms.
Thoracic Oncology
Investigation of malignant lung cancer across histologies and molecular alterations.
- Non‑small cell lung cancer with EGFR mutations
- ALK‑positive NSCLC
- KRAS G12C‑mutant NSCLC
- Small‑cell lung cancer second‑line therapy
Emphasis on patients with brain metastases and prior systemic lines.
Gastrointestinal and Hepatobiliary Oncology
Clinical evaluation of malignancies of the gastrointestinal tract and liver.
- Colorectal carcinoma with MSI‑high status
- Gastric and gastro‑esophageal junction adenocarcinoma
- Pancreatic ductal adenocarcinoma
- Cholangiocarcinoma and biliary tract cancers
- Hepatocellular carcinoma
Includes studies on refractory disease and molecularly defined subgroups.
Hematologic Malignancies
Targeted studies of blood‑derived cancers addressing both acute and chronic entities.
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Multiple myeloma
- Diffuse large B‑cell lymphoma
- Mantle cell lymphoma
Research spans frontline therapy, maintenance and novel immunotherapies.
Molecularly Targeted and Rare Tumors
Trials directed at rare or genetically defined cancers requiring precision approaches.
- RET‑fusion positive NSCLC
- NTRK‑rearranged solid tumors
- Neuroendocrine tumors of the lung and pancreas
- Mesothelioma
- Advanced solid tumors with high tumor mutational burden
Leverages biomarkers such as MSI‑H, dMMR and TMB for patient selection.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.